Samenvatti
ng MONOKLONALE
minisympo
ANTISTOFFEN
Biomedische
Wetenschappen -
sium2019/2020
Door Nicole (studente BMW)
,Inhoudsopgave
1. Antistoffen in onderzoek....................................................................................................................3
Monoklonaal en polyklonaal..............................................................................................................3
Immunoassay......................................................................................................................................3
Immunoprecipitatie en immuno-affiniteitschromatografie................................................................3
Western Blot en SDS-PAGE.............................................................................................................4
Cytokine bead assay...........................................................................................................................5
Immunohistochemie...........................................................................................................................5
Antigeen-antilichaam interactie.........................................................................................................6
2. Aantonen van antistoffen...................................................................................................................7
Inleiding..............................................................................................................................................7
Diagnose technieken..........................................................................................................................7
ELISA...................................................................................................................................................7
Indirecte methode..........................................................................................................................8
Competitieve methode...................................................................................................................8
Double antigen methode................................................................................................................8
Diagnose.............................................................................................................................................9
PCR...............................................................................................................................................10
3. Ziekmakende antistoffen deel 1.......................................................................................................11
Klinische presentatie en histologie...................................................................................................11
Pathofysiologie.................................................................................................................................11
Antilichamen op zich kunnen de ziekte veroorzaken....................................................................12
Desmogleïne compensatie model.................................................................................................12
Dsg nonassembly depletion..........................................................................................................13
T-cellen.........................................................................................................................................13
Pemphigus antilichamen..............................................................................................................13
Medicijnen........................................................................................................................................14
Prednison......................................................................................................................................14
Immuun onderdrukkende medicijnen..........................................................................................14
Rituximab......................................................................................................................................14
4. Ziekmakende antistoffen deel 2.......................................................................................................15
IgE-verwante chronische ziekten......................................................................................................15
Omalizumab.....................................................................................................................................15
Omalizumab bij astma..................................................................................................................16
5. Genezende antistoffen deel 1...........................................................................................................17
1
, Mechanismen voor het doden van tumoren....................................................................................17
Directe doding van tumorcellen...................................................................................................17
Immuungemedieerde celdoding...................................................................................................17
Vasculaire en stromale ablatie......................................................................................................18
Ontwikkeling van antilichamen........................................................................................................18
Immuunreactie.................................................................................................................................19
6. Genezende antistoffen deel 2...........................................................................................................19
Reumatoïde Artritis (RA)...................................................................................................................19
Medicijnen voor RA..........................................................................................................................20
Biologics........................................................................................................................................20
Tumor necrose factor remmers (TNF-remmers)...........................................................................21
Interleukine-6 remming................................................................................................................22
B-cel modulatie.............................................................................................................................22
T-cel modulatie.............................................................................................................................22
2
ng MONOKLONALE
minisympo
ANTISTOFFEN
Biomedische
Wetenschappen -
sium2019/2020
Door Nicole (studente BMW)
,Inhoudsopgave
1. Antistoffen in onderzoek....................................................................................................................3
Monoklonaal en polyklonaal..............................................................................................................3
Immunoassay......................................................................................................................................3
Immunoprecipitatie en immuno-affiniteitschromatografie................................................................3
Western Blot en SDS-PAGE.............................................................................................................4
Cytokine bead assay...........................................................................................................................5
Immunohistochemie...........................................................................................................................5
Antigeen-antilichaam interactie.........................................................................................................6
2. Aantonen van antistoffen...................................................................................................................7
Inleiding..............................................................................................................................................7
Diagnose technieken..........................................................................................................................7
ELISA...................................................................................................................................................7
Indirecte methode..........................................................................................................................8
Competitieve methode...................................................................................................................8
Double antigen methode................................................................................................................8
Diagnose.............................................................................................................................................9
PCR...............................................................................................................................................10
3. Ziekmakende antistoffen deel 1.......................................................................................................11
Klinische presentatie en histologie...................................................................................................11
Pathofysiologie.................................................................................................................................11
Antilichamen op zich kunnen de ziekte veroorzaken....................................................................12
Desmogleïne compensatie model.................................................................................................12
Dsg nonassembly depletion..........................................................................................................13
T-cellen.........................................................................................................................................13
Pemphigus antilichamen..............................................................................................................13
Medicijnen........................................................................................................................................14
Prednison......................................................................................................................................14
Immuun onderdrukkende medicijnen..........................................................................................14
Rituximab......................................................................................................................................14
4. Ziekmakende antistoffen deel 2.......................................................................................................15
IgE-verwante chronische ziekten......................................................................................................15
Omalizumab.....................................................................................................................................15
Omalizumab bij astma..................................................................................................................16
5. Genezende antistoffen deel 1...........................................................................................................17
1
, Mechanismen voor het doden van tumoren....................................................................................17
Directe doding van tumorcellen...................................................................................................17
Immuungemedieerde celdoding...................................................................................................17
Vasculaire en stromale ablatie......................................................................................................18
Ontwikkeling van antilichamen........................................................................................................18
Immuunreactie.................................................................................................................................19
6. Genezende antistoffen deel 2...........................................................................................................19
Reumatoïde Artritis (RA)...................................................................................................................19
Medicijnen voor RA..........................................................................................................................20
Biologics........................................................................................................................................20
Tumor necrose factor remmers (TNF-remmers)...........................................................................21
Interleukine-6 remming................................................................................................................22
B-cel modulatie.............................................................................................................................22
T-cel modulatie.............................................................................................................................22
2
